med onc @JHBreastGyn @HopkinsKimmel @HopkinsMedicine, @JohnsHopkins professor, @CLOSLER member. @ASCO fellow. @NCICTEP_ClinRes. @SusanGKomen scholar 🇧🇷/🇺🇲
Baltimore, MD
Joined April 2008
- Tweets2.6K
- Following3.1K
- Followers3.4K
- Likes5.7K
Why #ClinicalTrials? Because they matter. They help us develop the best interventions & treatments, and often ensure patients receive the best possible care. #BCSM #ItTakesAVillage @JHBreastGyn @hopkinskimmel
October is #breastcancerawarenessmonth. @awolff from @hopkinskimmel explains the benefit of clinical trials to both patients undergoing treatment and those who will be diagnosed in the future. #bcsm
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
Don’t miss Dr. Erica Mayer (@elmayermd) presenting results from a Phase II study on neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated #BreastCancer, focusing on the ER+/HER2- cohort, at the #SABCS24 Rapid Fire 3 session. @TheTBCRC
🗓️ Friday, December 13th
⏰ 12:00 – 12:50 pm CST (1:00 – 1:50 pm EST)
📍 Hall 1
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
#SABCS24
Dr. @awolff: Must study impact of new #cancer drugs on reproductive health.
⌛️ He believes we are under-utilizing ovarian suppression & over-utilizing chemo in premenopausal w/ #breastcancer, & window to answer this Q definitively in #bcsm #clinicaltrials is closing.
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
Excited to see these @TheTBCRC presentations at SABCS 2024!
-TBCRC 052: Does margetuximab provide benefit over trastuzumab in neoadjuvant HER2+ disease?
-TBCRC 056: neoadjuvant PARP + IO in ER+ BRCA1/2 or PALB2 mut breast cancer?
- and more!
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
We are excited to have this trial open for patients with #metastatic #breastcancer treated an NCI community oncology practices #NCORP
@eaonc @awolff @ruthcarlosmd @ilana_graetz @LynneWagnerPhD
#ClinicalTrial EAQ221CD/CONCURxP monitors CDK4/6 inhibitor medication use with text message reminders & alerts for patients treated for #BreastCancer. For more information: bit.ly/EAQ221CD #bcsm cc: @GelarehSadigh, @ilana_graetz
It was a treat to do the Highlights of the Day I - Breast Ca Metastatic, and contextualize the great work of presenters and discussants. Thou shalt not forget to watch the fantastic talk by discussant @MayoClinic Dr. Ciara O'Sullivan.
Taking a moment to acknowledge that many places, especially in third world countries, lack access to essential drugs and resources. We are fortunate to have more in the US.
A shout out to Dr. O’Sullivan for acknowledging that treatment paradigms are not applicable everywhere, we often take that for granted ‼️
#HealthEquity #AccessToCare #ASCO24 #bcsm
@MayoCancerCare @ASCO @OncoAlert
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
RxPONDER: AMH (low levels associated w/ diminished ovarian reserve) in women classified as premenopausal
If low AMH --> no benefit from adj chemo
If med/high AMH--> ⬆️4.4% in 5 yr DRFS w/ chemo
Suggests:chemo impact may be due to impact on ovarian fxn
@OncoAlert #ASCO24
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
Dr. Nadine Tung discusses TBCRC048 at #ASCO24 - olaparib is effective in patients with MBC with inherited PALB2 mutation or tumor acquired BRCA1 or BRCA2 mutation. Benefit in initial trial confirmed in a larger group of patients @TheTBCRC @OncoAlert
So grateful, @TarahBallinger. We are privileged that you chose to bring your brilliance to @eaonc and brighten the work we do to improve care for our patients. @NCICancerCtrl #ASCO24
#TrialsThatImpactPatientCare Congratulations to the @eaonc EAZ171 Team! #ASCO24 See full press release ecog-acrin.org/press-release… and simultaneous JCO paper ascopubs.org/doi/10.1200/JCO…
Check out @JCO_ASCO Podcast: "EAZ171: Predictors of TIPN in Black women with #BreastCancer" w/ Dr. @ShannonWestin & Dr. @BryanSchne90417. EAZ171 was presented at the #ASCO24 Annual Meeting.
@TarahBallinger @NCIprevention #NCORP @SusanGKomen @VBFoundation jcopodcast.libsyn.com/eaz171…
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
ETHAN - groundbreaking new @TheTBCRC trial for male breast cancer led by PI Dr. Pablo Leone. #ASCO24
Learn more at classic.clinicaltrials.gov/c…
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
PI Dr. Tiffany Traina presenting the actively enrolling TBCRC058 trial #ASCO24 @RitaNandaMD
Find more info at: classic.clinicaltrials.gov/c…
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
Tomorrow #ASCO24 check out @NTungMD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewarding studies I’ve managed in the last decade and a testament to the power of investigator-initiated research @BIDMChealth @DFCI_BreastOnc @TheTBCRC
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
TBCRC048 is a collaborative IST led by #DFHCC and was open at 11 academic centers across the US via @TheTBCRC - thank you to the incredibly dedicated study teams at each of the sites and, most importantly, the 114 participants, many of whom traveled great distances for the study
Tomorrow #ASCO24 check out @NTungMD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewarding studies I’ve managed in the last decade and a testament to the power of investigator-initiated research @BIDMChealth @DFCI_BreastOnc @TheTBCRC
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
As seen today at #ASCO24 - TBCRC026, HER2-E and tumors with increased immune signaling more likely to respond to HER2-directed therapy in ER-/HER2+ breast cancer treated with neoadjuvant HP without chemo. @TheTBCRC @HennessyMaeve
This is what qualifies for an oncologist to be in the presence of a rock star @NIHDirector ! #asco24 @judywawira @RamalingamMD
Training & Promoting the next generation of breast cancer leaders, and of course designing the next generation of trials to improve patient outcomes.
This Post is from an account that no longer exists. Learn more
What a trio of ACRA Award recipients, including @hopkinskimmel @JHBreastGyn Cesar Santa-Maria, MD! Congratulations to all in the Class of #ASCO24 @ConquerCancerFd awardees and their mentors! @ASCO
